ロード中...
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor. Phase I and II studies demonstrated clinical efficacy in both BRCA-mutated (inclusive of germline and somatic) ovarian tumors and ovarian tumors with homologous recombination deficiency (HRD) loss...
保存先:
| 出版年: | Onco Targets Ther |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5488752/ https://ncbi.nlm.nih.gov/pubmed/28790837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S114714 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|